Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ropivacaine hydrochloride
Drug ID BADD_D01968
Description Ropivacaine is an aminoamide local anaesthetic drug commonly marketed by AstraZeneca under the trade name Naropin. It is present as a racemic mixture of the enantiomers containing equal proportions of the “S” and “R” forms. The marketed form contains the single S-enantiomer as the active ingredient.
Indications and Usage Used in obstetric anesthesia and regional anesthesia for surgery.
Marketing Status Prescription; Discontinued
ATC Code N01BB09
DrugBank ID DB00296
KEGG ID D04048
MeSH ID D000077212
PubChem ID 175804
TTD Drug ID D09RHQ
NDC Product Code 70069-063; 43066-015; 0409-9300; 65145-108; 43066-023; 55150-201; 63323-285; 55150-196; 63323-286; 55150-195; 46014-1058; 25021-671; 0409-9301; 65145-109; 63323-287; 55150-198; 70518-2681; 63323-288; 49386-025; 55150-199; 65145-107; 48954-722; 0143-9265; 67184-0022; 25021-652; 0143-9263; 70069-061; 55150-197; 76339-124; 0404-9924; 70069-064; 17478-081; 43066-019; 51552-1590; 70516-0165; 0143-9264; 0409-9302; 49452-6303; 0143-9266; 52584-286; 43066-027; 65372-1159; 70069-062; 17478-082; 65145-110; 0409-9303; 61876-0071; 55150-200; 70069-065; 70069-066; 70069-067
Synonyms Ropivacaine | 1-Propyl-2',6'-pipecoloxylidide | 1 Propyl 2',6' pipecoloxylidide | Naropin | Ropivacaine Monohydrochloride | Ropivacaine Hydrochloride | AL 381 | AL-381 | AL381 | Naropeine | LEA 103 | LEA-103 | LEA103 | Ropivacaine Monohydrochloride, (S)-isomer
Chemical Information
Molecular Formula C17H27ClN2O
CAS Registry Number 98717-15-8
SMILES CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ventricular arrhythmia02.03.04.006--
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Foetal acidosis18.03.02.002--Not Available
Deep vein thrombosis24.01.02.003--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Rectal tenesmus15.05.03.011; 07.03.03.001--Not Available
Neonatal tachypnoea22.11.01.003; 18.04.09.003--Not Available
Post procedural complication12.02.05.018--Not Available
Metabolic disorder14.11.01.001--Not Available
Muscle relaxant therapy25.16.01.001--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Neurological symptom17.02.05.010--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.01.01.003--Not Available
Mental disorder19.07.01.002--Not Available
Neonatal infection18.04.12.001; 11.01.08.032--Not Available
Central nervous system stimulation25.04.01.001--Not Available
Respiratory disorder neonatal22.11.01.002; 18.04.09.002--Not Available
Ill-defined disorder08.01.03.049--Not Available
Extradural abscess17.06.07.003; 11.01.03.006--Not Available
Neonatal complications of substance abuse19.07.02.015; 18.04.13.002; 12.03.01.050--Not Available
Cranial nerve paralysis17.04.01.002--Not Available
Pulmonary function test decreased13.19.01.001--Not Available
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages